ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1339

A Pilot Study Investigating the Tolerability and Pharmacodynamic Effect of Single Intravenous/Subcutaneous Doses of Olokizumab, an Anti-Interleukin-6 Monoclonal Antibody, in Patients with Rheumatoid Arthritis

Roy Fleischmann1, Alan J. Kivitz2, Frank Wagner3, Jeffrey A. Feinstein4, Uwe Fuhr5, Jürgen Rech6, Jagdev Sidhu7, Philip L. Hill8, Ruth Oliver8 and Kosmas Kretsos9, 1University of Texas Southwestern Medical Center, Dallas, TX, 2Altoona Center for Clinical Research, Duncansville, PA, 3Charité Research Org GmbH, Berlin, Germany, 4San Antonio, TX, 5Hospital of the University of Cologne (AöR), Köln, Germany, 6Medizinische Klinik 3, University of Erlangen-Nuremberg, Erlangen, Germany, 7CSL Limited, Parkville, Australia, 8UCB Celltech, Slough, United Kingdom, 9UCB, Slough, United Kingdom

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: interleukins (IL) and rheumatoid arthritis (RA)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Rheumatoid Arthritis Treatment - Small Molecules, Biologics and Gene Therapy

Session Type: Abstract Submissions (ACR)

Background/Purpose: Olokizumab is a novel IL-6 inhibitor that selectively blocks the final assembly of the IL-6 signaling complex (gp80+gp130+IL-6). We report the safety, PK, and PD results from a pilot single-dose study in patients with rheumatoid arthritis (RA).

Methods: This was a randomized, double-blind, placebo-controlled study of RA patients who: were diagnosed by the 1987 ACR criteria; had >6 months’ disease duration; were treated with methotrexate 5–25 mg/week for at least 3 months prior to screening; had an elevated baseline high-sensitivity C-reactive protein (CRP; median 3.37, range 0.6–27.2 mg/L) with a reasonable spread that allowed robust characterization of the PD effect. At baseline, the mean DAS28 (CRP) was 3.07 (olokizumab) and 2.87 (placebo). Patients were randomized (3:1) to a single dose of olokizumab, either iv (0.1 or 1.0 mg/kg) or sc (1.0 or 3.0 mg/kg), or placebo. Primary objectives of the study included evaluating the PK/PD relationship between olokizumab and CRP, and the safety and tolerability of olokizumab over 12 weeks post dose.

Results: Of 40 randomized patients, 38 completed the 12-week follow-up. Dose-dependent and sustained suppression of plasma CRP followed all doses of olokizumab until the end of the study (except for the 0.1 mg/kg iv group). IL-6 levels were markedly reduced after olokizumab exposure, remaining suppressed for the duration of the study. Commonly reported AEs in olokizumab recipients included headache, infection, decreased white blood cells (WBC), and abnormal liver function tests (LFT), with no dose relationship to severity, grade, or frequency of reported events. Laboratory abnormalities included: reductions in WBC and elevated LFT, cholesterol, and triglycerides. Two serious AEs were reported: 1 for placebo (grade 2 Bowen’s disease) and 1 for olokizumab 1.0 mg/kg sc (worsening of RA). Two patients withdrew: 1 placebo (worsening of RA) and 1 olokizumab 1.0 mg/kg sc (protocol deviation). Dose-related reductions in complement C3 and C4 were seen. The terminal elimination t½ of olokizumab in plasma was consistent regardless of route of administration or dose, with an overall median of 31 days. For the 1.0 and 3.0 mg/kg sc dose groups, the mean Cmax was 6.29 and 19.1 μg/mL, achieved within a median tmax of 13 and 7 days, respectively. Bioavailability determined from PK/PD modeling, pooling data from the first-in-human study1 and this study, was 76%. Non-compartmental analysis, based solely on data from this study, yielded a bioavailability of 66%.

Description: C:Usersmatthew.hillDesktop12-06-26 RA0010 ACR abstract SUBMITTED_filesimage002.gif

Conclusion: In RA patients, single doses of ≤3mg/kg sc olokizumab demonstrated prolonged suppression of CRP, a marker of inflammation, although CRP in the 0.1 mg/kg iv group showed some recovery after 28 days; all doses were well tolerated. These results provided the rationale for a further study to investigate the clinical efficacy of olokizumab in RA.

Reference: 1. Ann Rheum Dis 2011;70(Suppl3):471


Disclosure:

R. Fleischmann,

Genentech Inc, Roche, Abbott, Amgen, UCB, Pfizer, BMS, Lilly, Sanofi Aventis, Lexicon, MSD, Novartis, BiogenIdec, Astellas, Astra-Zeneca, Jansen,

5,

Roche, Abbott, Amgen, UCB, Pfizer, BMS, Lilly, Sanofi Aventis, Lexicon, Novartis, Astellas, Astra-Zeneca, Jansen, HGS,

2;

A. J. Kivitz,

Genentech and Biogen IDEC Inc.,

5,

Bristol-Myers Squibb,

8,

Takeda,

8,

Forest Laboratories,

8,

Pfizer Inc,

8;

F. Wagner,
None;

J. A. Feinstein,
None;

U. Fuhr,
None;

J. Rech,
None;

J. Sidhu,
None;

P. L. Hill,

Employed by UCB,

3;

R. Oliver,

Employed by UCB,

3;

K. Kretsos,

Employed by UCB,

3.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/a-pilot-study-investigating-the-tolerability-and-pharmacodynamic-effect-of-single-intravenoussubcutaneous-doses-of-olokizumab-an-anti-interleukin-6-monoclonal-antibody-in-patients-with-rheumatoid-a/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology